U.S. opium and cannabis API market seen reaching $17.9 billion by 2033

Coherent Market Insights says the U.S. opium and cannabis active pharmaceutical ingredients market could grow from $6.83 billion in 2026 to $17.86 billion by 2033. The forecast points to a 14.7% compound annual growth rate and highlights demand, competition and segment trends across opium and cannabis APIs.

Why it matters: - The U.S. opium and cannabis API market is projected to more than double by 2033, signaling a major opportunity for suppliers, drug developers and investors. - The forecast points to rising demand in biopharmaceuticals and research, where API availability and competitive positioning can shape future growth.

What happened: - Coherent Market Insights published a new forecast for the U.S. Opium and Cannabis API Market covering 2026 to 2033. - The report estimates the market will grow from $6,832.0 million in 2026 to $17,863.8 million by 2033. - The projected compound annual growth rate is 14.7%. - The report was released Aug. 13, 2026, in Burlingame, California. - The study includes global and country-level forecasts, competitive landscape analysis and supply chain evaluation. - The report also examines market dynamics, technological advancements, investment opportunities, financial performance and a SWOT analysis. - A sample copy is available via the report request page.

The details: - The report breaks the market down by API type and end user. - The API types covered are opium and cannabis. - The end users covered are biopharmaceutical companies and research institutes. - The research evaluates growth drivers, restraints, trends, opportunities and challenges affecting the market. - The report says it provides historical data, future forecasts, revenue share analysis of key companies, regional market insights and industry trend tracking. - The competitive set listed in the report includes Mallinckrodt Pharmaceuticals, Alcaliber S.A., Johnson Matthey Plc, Noramco Inc., Cambrex Corporation, Alps Pharmaceutical Ind. Co., Ltd., EuroAPI, Purisys LLC, Catalent Inc. and MediPharm Labs Corp. - The competitive analysis looks at market share, revenue, product portfolio, production capacity, gross margins and sales performance. - The report highlights competitive developments such as expansions, product launches, acquisitions and collaborations. - The study says it includes Porter’s Five Forces and strategic recommendations for decision-making and investment planning. - The report says it offers regional insights, company profiles, product comparisons and SWOT analysis.

Between the lines: - The forecast reflects a market still defined by regulation, specialized manufacturing and a concentrated supplier base. - The emphasis on supply chain evaluation and competitive benchmarking suggests buyers are looking for resilience as well as growth. - The inclusion of research institutes alongside biopharmaceutical companies points to demand that is tied to both development pipelines and scientific research.

What's next: - The report points to continued tracking of regional demand patterns, segment performance and competitive moves through 2033. - Market participants are likely to use the forecast to guide capacity planning, partnerships and investment decisions. - Coherent Market Insights says the report concludes with findings, stakeholder implications and strategic recommendations for future action.